Disease Landscape and Forecast 인사이트

MARKET OUTLOOKAtherosclerotic cardiovascular disease (ASCVD) broadly covers coronary artery disease, including acute coronary syndrome, a history of myocardial infarction, stable or unstable angina…

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically…

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic…

DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…

Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung…